Company Comparison
Carmat vs 54gene
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Carmat | 54gene |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Vélizy-Villacoublay, France | Lagos, Nigeria |
| Founded | 2008 | 2019 |
| Status | Active | Active |
| Last Funding Stage | IPO | Series B |
| Total Funding | €63M | $45M |
| Valuation | — | — |
What They Build
Carmat
Carmat develops artificial heart devices designed to replace the function of a failing heart in patients with end-stage heart failure.
54gene
African genomics research company advancing precision medicine through genetic research focused on African populations.
Key Investors
Carmat
Sector Overlap
Both Carmat and 54gene operate in Biotech.
Browse all Biotech companies →Sponsored
AArchstone
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
LP portal & reportingCapital callsPortfolio tracking$297/moNo AUM fees
Now in alpha with select funds. 14-day trial available.